Aethlon Medical Income Statement 2026-2010 | AEMD

Brief overview of financial performance at Aethlon Medical

The figures are compared over a five-year interval. The revenue attributed to Aethlon Medical moved from $150 thousand to $574 thousand between the two endpoints. The total change was +283.8%, with a CAGR of approximately 30.9%. This pace points to rapid expansion of the business.

The gross result shifted from −2.5 million dollars to −3.9 million dollars, or −55.7%. The cost base moved more slowly than the top line, which supported margins. Comparing the endpoints gives gross margins of −1661% and −673.8%. The margin shift points to a more favorable sales-and-cost structure.

The operating result measured by EBITDA moved from −4.8 million dollars to −11.7 million dollars, or −143.1%. The operating result developed less favorably than sales. EBITDA margin moved from −3205% to −2030.1%. Higher profitability strengthens the quality of operating growth.

Net income moved from −$5.7 million at the start to −$12 million at the end. The loss widened and increased the financial risk.

Over the period, capitalization shifted from 16.5 million dollars to 863 thousand dollars (−94.8%). Capitalization lags the underlying business improvement.

Conclusion

The results contain several connected negative signals. The constructive conclusion rests on better sales economics, a larger revenue base and higher operating efficiency. The overall view is constrained by declining net profitability, lower investor confidence and limited operating profitability. Investors should continue to monitor margins, costs, and earnings quality.